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Abstract
Vascular endothelial growth factor C (VEGF-C) binding to its
tyrosine kinase receptor VEGFR-3 drives lymphatic vessel growth
during development and in pathological processes. Although the
VEGF-C/VEGFR-3 pathway provides a target for treatment of cancer
and lymphedema, the physiological functions of VEGF-C in adult
vasculature are unknown. We show here that VEGF-C is necessary
for perinatal lymphangiogenesis, but required for adult lymphatic
vessel maintenance only in the intestine. Following Vegfc gene
deletion in adult mice, the intestinal lymphatic vessels, including
the lacteal vessels, underwent gradual atrophy, which was aggra-
vated when also Vegfd was deleted. VEGF-C was expressed by a
subset of smooth muscle cells adjacent to the lacteals in the villus
and in the intestinal wall. The Vegfc-deleted mice showed defective
lipid absorption and increased fecal excretion of dietary choles-
terol and fatty acids. When fed a high-fat diet, the Vegfc-deficient
mice were resistant to obesity and had improved glucose metabo-
lism. Our findings indicate that the lymphangiogenic growth
factors provide trophic and dynamic regulation of the intestinal
lymphatic vasculature, which could be especially important in the
dietary regulation of adiposity and cholesterol metabolism.
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Introduction
Lymphatic vessels regulate tissue fluid homeostasis, immune cell
trafficking, and dietary fat absorption, and their malfunction leads
to chronic edema and impaired immune responses (Cueni & Detmar,
2008; Alitalo, 2011; Koltowska et al, 2013). Lymphangiogenesis
occurs during pathological processes such as inflammation and
tumor metastasis and inhibitors of lymphangiogenic growth factors
and their receptors are currently in clinical trials in human
cancer patients (Alitalo, 2011). The development of the lymphatic
vasculature is guided primarily by VEGF-C-mediated activation of
VEGFR-3, which is the main VEGF receptor expressed by lymphatic
endothelial cells (Makinen et al, 2001; Karkkainen et al, 2004). In
the absence of VEGF-C, the development of lymphatic vessels is
arrested during their initial spouting from embryonic veins
(Karkkainen et al, 2004). VEGF-D, the second VEGFR-3 ligand,
cannot compensate for the absence of VEGF-C during development,
but it induces lymphangiogenesis when overexpressed and its
deletion during development results in mild lymphatic vessel atro-
phy in the skin (Rissanen et al, 2003; Karkkainen et al, 2004;
Alitalo, 2011; Paquet-Fifield et al, 2013; Astin et al, 2014).
During the postnatal period, the lymphatic vessels continue to
expand, and in the intestine, the lacteal vessels grow into the intesti-
nal villi to facilitate lipid absorption from the fat-rich milk (Kim
et al, 2007). Lipid absorption allowed Gaspare Aselli to discover
lymphatic vessels by their content of milky fluid in the 17th century
(Dixon, 2010). Recent studies have shown that the lacteal vessels
are actively involved in lipid transport from the small intestinal
epithelium to the lymphatic system and further to the blood circula-
tion, although the detailed mechanisms have not been elucidated
(Dixon, 2010). In several genetic mouse models of impaired
lymphatic development, including Vegfr3 and Vegfc hypomorphic
mice, and Chy mice that have a missense point mutation in Vegfr3,
lipid-rich chylous ascites develops after birth but resolves before
weaning (Karkkainen et al, 2001, 2004; Haiko et al, 2008).
However, the possible function of lymphangiogenic growth factors
in the normally developed adult intestine is not known.
Here we have studied the role of VEGF-C in lymphatic vessel
growth, maintenance, and function in neonatal and adult mice by
using a mouse model that allows effective Vegfc gene deletion by
the Cre-Lox system (Aspelund et al, 2014). We demonstrate that
VEGF-C has a crucial role in the maintenance of the intestinal
lymphatic vessels and dietary fat absorption.
Results and Discussion
Vegfc gene deletion arrests lymphatic vessel growth in the
developing intestine
In Vegfc gene-deleted embryos, lymphatic vessel sprouting from the
major embryonic veins at embryonic day (E) 10.5 is arrested and
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the embryos die between E15.5 and E17.5 (Karkkainen et al, 2004).
To study how the loss of VEGF-C affects lymphatic vessel develop-
ment during the last trimester of fetal development, we crossed the
Vegfcflox/flox mice (Aspelund et al, 2014) with mice expressing the
universal deletor R26Cre-ERT2 (Ventura et al, 2007). To delete Vegfc
in the R26Cre-ERT2;Vegfcflox/flox embryos, pregnant females were
injected with 4-OH tamoxifen at E12.5 and E13.5. Analysis at E18.5
indicated that the Vegfc-deleted (VCiDR26) embryos lack mesenteric
lymphatic vessels either completely (data not shown) or exhibit
lymphatic vessel fragments and blind-ended lymphatic stubs that
extend toward the intestinal wall (Fig 1A and B). Deletion of Vegfc
at E14.5 blocked the maturation of the mesenteric collecting
lymphatic vessels. The developing vessels lacked valves and were
much thinner than in the wild-type (WT) Vegfcflox/flox embryos
5.21
E
T
H
O-4
5.81
E
sisylan
A
A B
C D
E G HF
WT VCiΔR26
VCiΔR26
VCiΔR26
VCiΔR26
VCiΔR26
  LYVE1
PECAM1 
PROX1
I J
K L
WT
5.41
E
T
H
O-4
5.81
E
sisylan
A
LYVE1VEGFR-3
O PM N
10 20 30 
mo 
Vegfd
Vegfc
i
+/+ 
+/+ 
+/+ 
+/+ 
+/+ 
–/–
–/– 
–/– 
- 
- 
1  
2  
3  
3  
6  
6  
LYVE1  area % 
Q R *
M
TA
M
O
XI
FE
N
 a
t 2
 m
o.
 A
na
ly
si
s 
1-
6 
m
o.
 la
te
r 
S T
U
LYVE1
PECAM1
N
O
P
Q
R
S
T
4-
O
H
T 
P1
-P
4 
- A
na
ly
si
s 
P6*
*
*
*
WT
WT
WT
#
§
**
***
*
Figure 1. VEGF-C is required for lymphatic vessel growth in the developing intestine and for the intestinal lymphatic vessel maintenance in adult mice.
Mice received tamoxifen as indicated in the figure. Immunofluorescence analyses from the intestine were performed in (A–H) embryos, (I–L) pups, and (M–U) adults.
A–D Mesenteric blood (PECAM1, red) and lymphatic vessels (LYVE1, green; PROX1, gray). Asterisks indicate lymphatic valves, arrow indicates a lymphatic vessel stub,
and arrowhead indicates an isolated lymphatic vessel fragment
E–H Blood vessels (PECAM1, green) and lymphatic vessels (VEGFR-3, red) in the small intestinal wall.
I, J Detection of chylous ascites (arrows) in the VCiDR26 mice at P6.
K, L LYVE1 staining of intestinal lymphatic vessels at P6.
M–T LYVE1 staining of lymphatic vessels in the intestinal wall in adult mice. Genotypes and deletion lengths are indicated in (U).
U Quantification of LYVE1 areas in (M–T). Length of the iΔVegfc gene deletion is indicated in months (mo), and Vegfd indicates the VEGF-D genotype. Data are
represented as mean  SEM. Significant differences were determined using one-way ANOVA and Bonferroni post hoc analysis compared to WT intestine
represented in (M). *P = 0.003, **P = 0.001, ***P = 0.0008, ♯P = 0.0002, §P = 0.0001.
Data information: Scale bars: 200 lm in (A–H) and 400 lm in (K–T). n = 25 (M); 5 (N); 8 (O); 7 (P); 6 (Q); 5 (R); 6 (S); 3 (T).
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(Fig 1C and D). In addition, the lymphatic vessels in the intestinal
wall failed to develop in the VCiDR26 embryos, whereas the blood
vessels were not affected (Fig 1E–H).
Lacteal lymphatic vessels develop after birth and are involved in
the absorption of dietary lipids from milk (Kim et al, 2007). In order
to determine whether VEGF-C is necessary for the formation of
lacteal vessels, we deleted Vegfc by daily 4-OH tamoxifen injections
to VCiDR26 and WT pups from postnatal day 1 (P1) to P4. Upon
necropsy at P6, chylous ascites was observed in the VCiDR26 pups,
but not in the WT littermates (Fig 1I and J). Immunofluorescence
staining of intestinal cross sections at P6 revealed that the lacteal
vessels failed to develop in the VCiDR26 pups (Fig 1K and L and
Appendix Fig S1A and B). Lymphatic vessels of the intestinal wall,
which develop during the intrauterine period, failed to expand upon
Vegfc deletion in postnatal period (Appendix Fig S1C–H). The
lymphatic vessel density in the skin was also reduced in the
VCiDR26 pups when compared to their WT littermates (Appendix
Fig S1I and J), whereas no changes were observed in the blood
vessel density (Appendix Fig S1K and L). Taken together, these
results indicate that VEGF-C is required for developmental and early
postnatal lymphangiogenesis.
VEGF-C is needed for lymphatic vessel maintenance only
in the intestine
The VCiDR26 mouse model allowed us to determine the role of
VEGF-C in the maintenance of lymphatic vessels in adult mice. To
induce Vegfc gene deletion, we administered tamoxifen to the mice
starting at 8 weeks of age. Real-time PCR analysis of several tissues
indicated that Vegfc mRNA levels in VCiDR26 mice were reduced to
2–15% of the levels in WT mice 3 months after tamoxifen treatment
(Appendix Table S1). Notably, whole-mount LYVE1 staining
revealed that the lymphatic vessels of the intestinal wall undergo a
gradual atrophy in the VCiDR26 mice (Fig 1M–U). Shorter lacteals
were observed already 3 weeks after Vegfc gene deletion (Appendix
Fig S2A), and after 3 months, the lacteals were strikingly thinner
and shorter, containing a reduced number of lymphatic endothelial
cells, suggesting that vessel atrophy was due to cell loss (Appendix
Fig S2B). Thus, the lymphatic vessel atrophy started from lacteals
and then progressed to the lymphatic network in the intestinal wall.
In contrast, even when Vegfc was effectively deleted for 6 months,
there were no changes in lymphatic vessel density in the lymph
nodes, ears, or trachea (Appendix Fig S3A–E).
The development of the lymphatic vasculature relies principally
on VEGF-C/VEGFR-3 signaling, while VEGF-D, the other known
ligand for VEGFR-3, cannot compensate for the lack of VEGF-C
signaling in Vegfc/ embryos (Karkkainen et al, 2004). Yet, VEGF-D
was found to induce lymphangiogenesis when overexpressed in
mouse tissues (Veikkola et al, 2001; Baluk et al, 2005). Constitutive
deletion of Vegfd had no effect on lymphatic vasculature in the adult
mouse intestine, in agreement with previous reports (Fig 1U)
(Baldwin et al, 2005). Surprisingly, however, conditional deletion of
Vegfc in the Vegfd/ mice resulted in more severe atrophy of the
intestinal lymphatic vessels than Vegfc deletion alone (Fig 1M–U).
These data indicate that VEGF-C is the primary trophic signal for the
maintenance of the intestinal lymphatic vessels, but VEGF-D can
partially compensate for the absence of VEGF-C. Because we did not
observe changes in Vegfd mRNA expression levels upon Vegfc
deletion (WT = 1.02  SEM 0.14 vs. VCiDR26 = 0.98  SEM 0.16),
it is likely that increased bioactive VEGF-D or increased VEGF-D
binding to VEGFR-3 partially compensates for the loss of VEGF-C.
VEGF-C is expressed by a subset of smooth muscle cells
in the intestine
Next, we sought to identify the cell types that express VEGF-C in
the adult intestine. Previous work from our laboratory showed
that VEGF-C is expressed in arterial smooth muscle cells (SMCs)
both in mice and humans (Partanen et al, 2000; Paavonen et al,
2002; Karkkainen et al, 2004). To define the cells expressing
VEGF-C and its receptors, we performed b-Gal staining of intesti-
nes from Vegfc/LacZ (Karkkainen et al, 2004), Vegfr3/LacZ (Du-
mont et al, 1998), and Vegfr2/LacZ (Shalaby et al, 1995) mice.
VEGF-C staining in the villi was weak in comparison with VEGFR-
3 and VEGFR-2 stainings, in lymphatic and blood vessels, respec-
tively (Fig 2A and B). Higher resolution analysis combined with
immunohistochemistry demonstrated VEGF-C expression in SMCs,
in the inner circular muscle layer of the intestinal wall, in arterial
smooth muscle, and in a subset of the SMC fibers in the villus
(Fig 2C). In the villi, the VEGF-C b-Gal signal was most prominent
adjacent to the LYVE1-counterstained lymphatic vessels (Fig 2D).
The intestinal wall of the Vegfc/LacZ mice showed a prominent
arterial b-Gal staining pattern, which was further analyzed by
PECAM-1 counterstaining of cross sections (Fig 2E), which
confirmed VEGF-C expression in the arterial SMCs. Whole-mount
confocal microscopy showed a close contact between the lacteal
vessels and the SMC fibers in the basal part of the villus where
also b-Gal staining of VEGF-C was detected (Fig 2D and F). These
results suggest that SMCs in the villi and in the intestinal wall
provide an important source for VEGF-C, which is required to
maintain the lymphatic vessel architecture in the intestine. It
should be noted that SMC contractility in the villi has been
suggested to be important for dietary lipid absorption and that
VEGF-C can induce contraction of the SMCs around the collecting
lymphatic vessels in normal and pathological conditions (Hosoya-
mada & Sakai, 2005, 2007; Breslin et al, 2007; Gogineni et al,
2013).
To determine whether the effect of VEGF-C on intestinal
lymphatic vessels is dependent on VEGFR-3, we analyzed the
Rosa26CreERT2;Vegr3flox/flox (R3iDR26) mouse model (Haiko et al,
2008). As expected, deletion of Vegfr3 for 3 months induced
lacteal vessel regression, similar to VEGF-C deletion (Appendix Fig
S4A and B). However, lymphatic vessel density in the intestinal
wall was not altered, suggesting that VEGF-C can signal via
VEGFR-2 to stabilize the lymphatic plexus. We have previously
shown that the tyrosine kinase inhibitor cediranib inhibits
lymphangiogenesis induced by adenoviral VEGF-C delivery into
adult mouse skin (Heckman et al, 2008). However, administration
of the tyrosine kinase inhibitor sunitinib at doses that block
VEGFR-2 and VEGFR-3 (Ki: VEGFR-3 17 nM/VEGFR-2 9 nM)
(Faivre et al, 2007) had no effect on the lacteal vessels, although
sunitinib significantly reduced blood vessel density in the intestinal
villi (Appendix Fig S4C–E), in line with a previous report (Kamba
et al, 2006). Thus, lacteal vessels appear to be more resistant than
blood vessels in the intestinal villus toward VEGFR tyrosine kinase
inhibition.
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Figure 2. Smooth muscle cells are the main source of VEGF-C in adult intestine.
A Overview of the small intestine cross section stained with nuclear red and highlighting the location of higher magnification images in (B–F); (I) for the
entire villus and (II) for the villus base. b-Gal staining pattern of the villus in wild-type (Ctrl), Vegfc/LacZ (VC), Vegfr3/LacZ (VR-3), and Vegfr2/LacZ (VR-2)
mice.
B Higher magnification images representing b-Gal staining of the villus base in Vegfc/LacZ mice.
C Vegfc/LacZ b-Gal staining reaction with smooth muscle actin (SMA) peroxidase staining.
D Vegfc/LacZ b-Gal staining and LYVE1 peroxidase staining.
E Surface image of Vegfc/LacZ b-Gal-stained intestine (left) and cross section counterstaining with PECAM1 (right).
F Immunofluorescence staining of lacteal lymphatic vessel (LYVE1), blood capillaries (PECAM1), and smooth muscle cells (SMA).
Data information: Arrows indicate the VEGF-C expression in arterial SMC, arrowheads indicate the VEGF-C expression in SMC fibers in the villus, and asterisks highlight
the VEGF-C expression in circular smooth muscle cell layer of the intestinal wall. Scale bars: 50 lm, except (C) inset 25 lm.
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Figure 3. Intestinal lymphatic vessel regression leads to impaired lipid absorption and resistance to diet-induced obesity.
Two-month-old mice received tamoxifen and were fed on high-fat diet (HFD) for seven weeks before analysis.
A Body weight change during seven weeks of HFD, expressed as average fold change in comparison with the starting weight. n = 16, WT; n = 6, Vegfd/; n = 16,
VCiDR26; n = 5, Vegfd/; VCiDR26.
B Body weight comparisons at seven weeks of HFD. Significant differences were determined using one-way ANOVA and Bonferroni post hoc analysis compared to WT.
*P = 0.004; **P = 0.003. n = 16, WT; n = 6, Vegfd/; n = 16, VCiDR26; n = 5, Vegfd/; VCiDR26.
C Glucose tolerance test (GTT) after six weeks of HFD. Significant differences were determined using unpaired two-tailed t-test. *P = 0.014; **P = 0.041. n = 5, WT;
n = 6, VCiDR26.
D Total fat weight, fat percentage from body composition measurements after six weeks of HFD, and weights of visceral fat (VF) and subcutaneous fat (SF) at
the time of necropsy. Significant differences were determined using unpaired two-tailed t-test. *P = 0.006; **P = 0.001; #P = 0.008; §P = 0.006. n = 4 in each
group.
E Food consumption during the fifth week of HFD. n = 9, WT; n = 10, VCiDR26.
F Whole-mount immunofluorescence staining of blood (PECAM1, red) and lymphatic vessels (LYVE1, green) in intestinal villi and intestinal wall.
G Quantification of the lacteal and villus length (solid and striped color bars, respectively) and the intestinal wall LYVE1+ area percentage from images represented
in (F). Significant differences were determined using unpaired two-tailed t-test. *P = 0.0002; **P = 0.00007. n = 5, WT; n = 6, VCiDR26.
H Free fatty acid (FFA) and cholesterol measurements from the feces after six weeks of HFD. Significant differences were determined using unpaired two-tailed t-test.
*P = 0.001; **P = 0.007. n = 5, WT; n = 6, VCiDR26.
Data information: Scale bars: 100 lm (villi) and 300 lm (intestinal wall). Data are represented as mean  SEM.
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Vegfc deletion reduces lipid absorption, inducing resistance to
diet-induced obesity
To determine whether VEGF-C is important for lipid absorption by
the intestinal lymphatic vessels, we performed an oral fat tolerance
test in mice in which VEGF-C had been deleted 3 months earlier.
The clearance of triglycerides from plasma was blocked by injection
of Triton WR 1339, an inhibitor of lipoprotein lipase activity (Otway
& Robinson, 1967). Analysis of triglyceride levels in serum after the
administration of an oil bolus showed that the VCiDR26 mice have
impaired lipid absorption when compared to WT mice (Appendix Fig
S5A). Although these results correlate with the lacteal regression, we
cannot exclude the involvement of possible other effects of Vegfc
deletion.
We further studied whether the reduction in dietary lipid absorp-
tion observed in the VCiDR26 mice has an impact on diet-induced
obesity in mice fed high-fat diet (HFD). Initial experiments in the
129SV/C57Bl/6J mixed genetic background did not reveal major dif-
ferences in body weight, but indicated that the VCiDR26 mice have
an improved glucose metabolism compared to WT mice (Appendix
Fig S5B and C). Interestingly, in the mixed background, the Vegfc-
deleted mice had reduced serum cholesterol levels, whereas fecal
cholesterol and free fatty acid (FFA) levels were increased in the
VCiDR26 mice, indicating impaired dietary lipid absorption
(Appendix Fig S5D). We further performed HFD feeding experiments
in the pure C57Bl/6J background, an established model of diet-
induced obesity. We deleted Vegfc in 8-week-old male mice and
started HFD feeding 4 weeks later. The VCiDR26 mice gained signifi-
cantly less weight and had better glucose tolerance than their WT
littermates, independently of concurrent Vegfd deletion (Fig 3A–C
and Appendix Fig S5E and F). At necropsy after HFD, very low
amounts of chyle were detected in one out of 16 Vegfc-deleted mice
and in two out of five Vegfc- plus Vegfd-deleted mice, indicating mild
lymphatic leakage. Body composition analysis showed that the
VCiDR26 mice had a significant reduction in total fat weight and fat
percentage, but no changes in lean weight in comparison with WT
littermates (Fig 3D and Appendix Fig S5G). The changes in fat accu-
mulation could not be explained by reduced caloric intake, since
food consumption was similar between the VCiDR26 and WT mice
(Fig 3E). As expected on the basis of our results from the mixed
background, Vegfc deletion induced intestinal lymphatic vessel atro-
phy and increased lipid excretion into the feces also in the C57Bl/6J
background (Fig 3F–H). No difference in body weight was observed
between WT and Vegfc-deleted mice on regular diet in which the
majority of calories are derived from carbohydrate. This further indi-
cates that the reduced body weight of the Vegfc-deleted mice on HFD
is a result of reduced dietary lipid absorption.
Use of the newly established Vegfc gene targeted mouse model
allowed us to determine the effect of chronic VEGF-C deficiency in
adult mice, where lymphatic vasculature is normally in a quiescent
state (Aspelund et al, 2014). The results of this study show that
intestinal lymphatic vessels in adults require trophic signals from
VEGF-C and that VEGF-D can only partially compensate for the loss
of VEGF-C to maintain their structure and function. The unexpected
finding that VEGF-C blockade affects only intestinal lymphatic
vasculature and lipid absorption may provide new therapeutic
opportunities. The specific VEGF-C/VEGFR-3 inhibitors that are
currently in phase I clinical trials for cancer treatment could
provide additional benefit for the treatment of obesity and cardio-
vascular disease by reducing the absorption of excess dietary lipids.
Further studies should address lacteal vessel atrophy and dietary fat
absorption in clinical trials employing VEGF-C/VEGFR-3 blocking
therapeutics.
Materials and Methods
Study approval
National Animal Experiment Board in Finland approved all experi-
ments involving the use of mice.
Mice and tissues
The mouse lines Vegfcfl/fl (Aspelund et al, 2014), Vegfr3fl/fl (Haiko
et al, 2008), Rosa26-CreERT2 (Ventura et al, 2007), Vegfd (Baldwin
et al, 2005), Vegfc/LacZ (Karkkainen et al, 2004), Vegfr3/LacZ
(Dumont et al, 1998), and Vegfr2/LacZ (Shalaby et al, 1995) have
been described previously. We used VCiDR26 mice in the mixed
C57Bl/6J and 129SV background or after backcrossing to the
C57Bl/6J strain for at least 7 generations. For induction of Cre-
mediated recombination in embryos, the mother was injected at the
indicated days with two consecutive intragastric doses of 4-OH
tamoxifen (4-OHT) (Sigma) (25 mg/ml dissolved in 100 ll ethanol/
olive oil). In the neonatal VCiDR26 or WT mice, the Cre-mediated
recombination was induced between P1 and P4 by daily intragastric
administration of 2 ll 4-OHT (25 mg/ml dissolved in ethanol).
Recombination in adult mice (7–8 weeks old) was done by intragas-
tric tamoxifen (Sigma, dissolved in corn oil at 2 mg/ml, 100 ll)
administration during five consecutive days. Detailed animal experi-
ment information can be found in the Appendix Supplementary
Materials and Methods.
Statistics
Quantitative data were compared between groups by two-tailed
unpaired t-test or one-way ANOVA followed by Bonferroni post
hoc test for multiple comparisons. Values are expressed as
mean  SEM. P-value < 0.05 was considered significant.
Expanded View for this article is available online:
http://emmm.embopress.org
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the obesogenic effect of excessive dietary lipid uptake.
Impact
Long-term inhibition of VEGF-C/VEGFR-3 is very well tolerated in
animal models. VEGF-C blockade induces atrophy of intestinal
lymphatic vessels and inhibits dietary lipid absorption, which could
provide new therapeutic opportunities for the treatment of obesity
and cardiovascular diseases.
EMBO Molecular Medicine Vol 7 | No 11 | 2015 ª 2015 The Authors
EMBO Molecular Medicine VEGF-C required for intestinal lymphatic vessels Harri Nurmi et al
1424
factor-d modulates caliber and function of initial lymphatics in the
dermis. J Invest Dermatol 133: 2074 – 2084
Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA,
Achen MG, Alitalo K (2000) VEGF-C and VEGF-D expression in
neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood
vessels in human tissues. FASEB J 14: 2087 – 2096
Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI,
Kholova I, Kauppinen RA, Achen MG, Stacker SA et al (2003) VEGF-D is the
strongest angiogenic and lymphangiogenic effector among VEGFs
delivered into skeletal muscle via adenoviruses. Circ Res 92: 1098 – 1106
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML,
Schuh AC (1995) Failure of blood-island formation and vasculogenesis in
Flk-1-deficient mice. Nature 376: 62 – 66
Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H,
Thurston G, McDonald DM, Achen MG et al (2001) Signalling via vascular
endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in
transgenic mice. EMBO J 20: 1223 – 1231
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L,
Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of
p53 function leads to tumour regression in vivo. Nature 445: 661 – 665
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 11 | 2015
Harri Nurmi et al VEGF-C required for intestinal lymphatic vessels EMBO Molecular Medicine
1425
